XOMA Co. (NASDAQ:XOMA - Get Free Report) CIO Bradley Sitko acquired 2,000 shares of the business's stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average cost of $24.70 per share, with a total value of $49,400.00. Following the acquisition, the executive now directly owns 5,045 shares of the company's stock, valued at $124,611.50. This trade represents a 65.68 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Bradley Sitko also recently made the following trade(s):
- On Friday, March 21st, Bradley Sitko purchased 4,134 shares of XOMA stock. The shares were bought at an average cost of $23.89 per share, with a total value of $98,761.26.
XOMA Price Performance
Shares of XOMA stock opened at $20.19 on Thursday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $241.86 million, a price-to-earnings ratio of -5.80 and a beta of 1.00. XOMA Co. has a 52 week low of $18.35 and a 52 week high of $35.00. The stock's 50-day simple moving average is $22.36 and its 200-day simple moving average is $26.30.
XOMA (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. As a group, analysts expect that XOMA Co. will post -1.41 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of XOMA. GAMMA Investing LLC lifted its holdings in XOMA by 1,063.8% during the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock worth $35,000 after buying an additional 1,585 shares during the period. BNP Paribas Financial Markets lifted its holdings in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock worth $43,000 after buying an additional 795 shares during the period. New York State Common Retirement Fund lifted its holdings in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after buying an additional 800 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of XOMA by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after purchasing an additional 1,183 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after purchasing an additional 2,009 shares during the last quarter. Institutional investors own 95.92% of the company's stock.
Analysts Set New Price Targets
XOMA has been the topic of several research analyst reports. StockNews.com downgraded XOMA from a "hold" rating to a "sell" rating in a research report on Thursday, April 3rd. HC Wainwright restated a "buy" rating and issued a $104.00 price objective on shares of XOMA in a research report on Friday, March 28th.
Check Out Our Latest Analysis on XOMA
XOMA Company Profile
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
